Full-Time

Strategic Account Manager

Posted on 7/4/2025

Travere Therapeutics

Travere Therapeutics

201-500 employees

Develops therapies for rare diseases

Compensation Overview

$170k - $221k/yr

+ Short-term Incentive + Long-term Incentive + Company Stock

Boston, MA, USA + 4 more

More locations: Providence, RI, USA | Trenton, NJ, USA | Hartford, CT, USA | New York, NY, USA

Remote

Candidates can be based in any of the listed states, and the role is fully remote.

Category
🤝Sales & Account Management (1)
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree required; advanced degree (MBA, MPH, MHA, PharmD, or MS) preferred.
  • Minimum 8 years of experience in the pharmaceutical, biotech, or healthcare industry; experience in nephrology, rare disease, or specialty care preferred.
  • Proven track record in strategic account management, healthcare system engagement, or field-based leadership roles.
Responsibilities
  • Lead strategic planning and execution across target healthcare organizations, aligning on shared clinical, operational, and economic priorities.
  • Identify and prioritize key accounts using a data-driven lens of market opportunity, institutional fit, and engagement readiness.
  • Develop tailored account engagement plans and reviews that elevate rare kidney disease care models.
  • Build high-value relationships with C-suite leaders, line directors, nephrologists, P&T stakeholders, care pathway leaders, and multidisciplinary teams.
  • Facilitate collaborative opportunities for co-developing best practices in clinical pathways, early diagnosis, and care transitions.
  • Identify opportunities to expand access, improve diagnosis rates, and support durable kidney preservation strategies.
  • Serve as the primary point of contact and orchestrator across internal partners including Medical Affairs, Field Medical (MSLs), Marketing, Thought Leader Liaisons (TLLs), Sales, Patient Advocacy, HEOR, Patient Services, and Market Access teams.
  • Lead internal business planning for strategic accounts, ensuring coordination of unbranded education, peer-to-peer programs, REMS coordination, and clinical protocol implementation.
  • Drive ecosystem collaboration to track key metrics, deliver regular performance updates, and action plans.
  • Capture, synthesize, and communicate actionable insights to internal stakeholders to shape strategy, education, and access programs.
  • Track and report progress against key account metrics including pathway adoption, patient identification trends, engagement outcomes, and resource utilization.
Desired Qualifications
  • The ideal candidate will embody Travere’s core values: Courage, Community Spirit, Patient Focus and Teamwork.
  • Deep understanding of value-based care, clinical integration, and the healthcare provider ecosystem (IDNs, ACOs, academic centers).
  • Ability to work cross-functionally, navigate ambiguity, and lead without authority.
  • Strong business acumen, communication, and consultative selling skills.
  • Demonstrated ability to build executive-level relationships and influence across matrixed healthcare organization.
  • Strong interpersonal and organizational skills and excellent verbal and written communication skills.
  • Successful record of creating and managing complex project plans, timelines, budgets, and critical paths.
  • Ability to adapt to modification and changes to project plans, demonstrating flexibility to implement new strategies and tactics to accommodate these changes.
  • Ability to travel 60 % domestic and internationally.

Travere Therapeutics focuses on creating and providing treatments for individuals with rare diseases, particularly those affecting the kidneys and metabolism. The company has developed commercial therapies such as Thiola and Thiola EC for cystinuria, and Chenodal for gallstones. Additionally, it is working on new treatments like sparsentan for conditions such as focal segmental glomerulosclerosis and IgA nephropathy. Unlike many other biopharmaceutical companies, Travere Therapeutics specifically targets rare diseases, which often have limited treatment options. The company's goal is to improve the lives of patients with these conditions by delivering effective therapies and offering support resources for patients and their families.

Company Size

201-500

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $144M funding supports clinical development and strategic initiatives.
  • EMA's expedited approval process could benefit Travere's European market pipeline.
  • Growing digital health platforms offer new patient engagement opportunities for Travere.

What critics are saying

  • Increased competition in IgA nephropathy market from Calliditas Therapeutics.
  • Challenging biotech market conditions may strain Travere's financial resources.
  • Loss of key personnel could impact clinical development projects.

What makes Travere Therapeutics unique

  • Focus on rare kidney and metabolic disorders sets Travere apart in biopharma.
  • Commercial products like Thiola and Chenodal provide a revenue stream for Travere.
  • Patient support programs enhance Travere's commitment to patient care and engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Travere Therapeutics
May 16th, 2025
Travere Therapeutics Announces Pricing of Public Offering of Common Stock

PDF Version Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million , before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024 , subject to customary closing conditions

Travere Therapeutics
Jan 23rd, 2025
Retrophin, LLC Completes Series A Financing | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

Travere Therapeutics
Jan 23rd, 2025
Retrophin Completes Reverse Merger With Desert Gateway, Inc. | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

CSIMarket
Nov 13th, 2024
Travere Therapeutics Raises $143.8M in Offering

Travere Therapeutics announced on November 12, 2024, that it raised approximately $144 million through a public offering, selling 8,984,375 shares at $16 each, including 1,171,875 shares from underwriters' overallotment options. The funds will support clinical development, operations, and strategic initiatives. This move comes amid challenging biotech market conditions and aims to address unmet medical needs in rare diseases. Travere also shared updates on its talent acquisition strategy.

Travere Therapeutics
Nov 11th, 2024
Travere Therapeutics Announces Pricing of Public Offering of Common Stock | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

INACTIVE